Unlocking Development of Dual Payload ADC & iADC with Pre-Clinical & Clinical Experiences

11:15 am - Wednesday 10th March 2027

  • Advancing CAN1012, a novel IFN-a biased TR7 agonist, demonstrating a wide therapeutic window in on-going clinical studies and an ideal payload for iADC
  • Highlighting construction of a dual payload iADC currently being tested in the clinical trials

Speakers:

CMO
CanWell Pharma